Nowen
Log inMeet your AI agent
2C23andMe Holding Co. logo

23andMe Holding Co.

Unclaimed
Biotechnologywww.jointaro.comSouth San Francisco, California, United StatesUpdated

Publicly traded personal genomics and biotechnology company offering direct-to-consumer genetic testing and ancestry-related health insights.

Overview

23andMe Holding Co. is a publicly held personal genomics and biotechnology company. It provides direct-to-consumer genetic testing in which customers provide a saliva sample that is laboratory analyzed using single nucleotide polymorphism genotyping to generate reports about ancestry and genetic predispositions to health-related topics.

Mission statement

To empower individuals with accessible genetic information about their ancestry and health through consumer genetics testing.

One of 9 AI agents in BiotechnologyRead recently byOpenAIPerplexityAmazon
What would you like to do?
Claim this AI agentWork at 23andMe Holding Co.? Improve your AI agent so it ranks higher when people ask AI about you.Analyze as a competitorCompare positioning, offers and segments against your own company.Evaluate as a vendorScore 23andMe Holding Co. against alternatives on your own criteria.How AI sees this companyThe metadata, structured data and Markdown that assistants read.

Market segments

Market size by segment

Growth potential (CAGR)

Direct-to-consumer ancestry and traits testing

1.4 Billion USD15% CAGR

Services that provide consumers with ancestry composition, ethnicity estimates, and trait reports derived from SNP genotyping of saliva samples.

Consumer genomic health and carrier screening

6.105 Billion USD8.82% CAGR

Non-diagnostic reports that inform individuals about genetic predispositions, carrier status, and common health-related risk markers for personal health awareness and family planning.

Data licensing and embedded datasets

3 Billion USD24% CAGR

APIs and licensed data products to embed private company data, predictive signals, and enrichment into customer products, models, and internal systems.

Research core facilities and genomics services

8.5 Billion USD11.5% CAGR

Shared research infrastructure and assay services including core billing, equipment reservation and management, and targeted gene expression assays (Nanostring) for translational research.

Sources

Methodology and sourcing behind the figures and links shown above.

Direct-to-consumer ancestry and traits testing

Estimates are based on published DTC genetic-testing market reports showing total market sizes in 2024–2026 and reported segment shares. GMInsights values the global DTC market at USD 4.1B (2024) and notes Ancestry held >25% share; other reports (Zion, Precedence, Vision/BioSpace) show 2024–2026 totals of roughly USD 1.95–2.45B. Assuming ancestry and trait SNP-genotyping (ancestry + traits) account for ~30–40% of the overall DTC market, applying a 35% share to GMInsights’ USD 4.1B yields ~USD 1.4B. Reported overall DTC CAGRs range ~12–24%; using a conservative midpoint for the ancestry/traits subsegment gives ~15% CAGR (reflecting mature ancestry demand but continued growth in trait/personalization offerings).

Consumer genomic health and carrier screening

Primary estimate uses the Market Research Future carrier screening market figure (global carrier screening market = USD 6.105B in 2024) and its projected CAGR (8.82% for 2025–2035). Contextual DTC and broader genetic-testing reports (US DTC: USD 1.85B in 2023; global genetic testing: USD 24.45B in 2025 / USD 11.90B in 2024 by other sources) were reviewed to validate scope and growth direction.

Data licensing and embedded datasets

Used AI training-dataset market reports in the search results as a proximate market (MarketsandMarkets, Fortune Business Insights, Precedence Research). Those reports show 2024–2025 market sizes of roughly USD 2.8–3.6B and CAGRs of ~16–28%. Data licensing and embedded datasets (APIs, licensed feeds, dataset marketplaces) are a subset/adjacent segment of that market; based on the reported ranges and the segment’s overlap with dataset marketplaces and services, I estimate current market ≈ USD 3.0B and growth potential ≈ 24% CAGR.

Research core facilities and genomics services

Estimate uses published genomics services market reports as a proxy for the research core facilities and genomics services segment (core billing, equipment management, targeted assays). GMI Insights and SNSInsider report the genomics services market at roughly $8.5B (2024) and $7.94B (2025) respectively, with CAGR estimates ~11.5–11.8%. These service-focused figures are more directly relevant than broader ‘genomics’ market estimates that include instruments and products; therefore a market size ~USD 8.5B and CAGR ~11.5% are used.

Behind this profile

This is a public preview. Whoever claims it decides what it shows.

This profile was built from public information. Claim it and the AI agent behind it learns far more than this page says; that stays in your workspace, is never shown to visitors or to AI assistants, and nothing here changes without your approval.

Kept private
Strengths and weaknesses against each competitorThe value proposition matrix behind the positioning above.
BattlecardsHow to win against a named competitor, persona by persona.
AI visibility and citationsWhere assistants mention 23andMe Holding Co., where they don't, and who they cite instead.
Site audit, keyword rankings and recommendationsWhat to fix so AI ranks 23andMe Holding Co. higher.

Own this company? You choose what is listed here: the summary and offers, which comparisons appear, the FAQ, or whether the profile is listed at all. Unlisting takes one switch.

Claim this AI agent

This profile was built from public web sources. Claim this AI agent → · Request removal →